Complement-targeted drug development requires more than measuring individual proteins. Integrating functional hemolysis assays, carefully selected serum or plasma samples, and multiplex biomarker analysis can provide a more reliable picture of complement activity, therapeutic inhibition, and biological response.
The complement system has become an important therapeutic target across immune-mediated, inflammatory, hematologic, and other disease areas. Yet its complexity creates a fundamental challenge for researchers: measuring the presence or concentration of a complement protein does not necessarily reveal whether the pathway is functionally active—or whether a therapeutic candidate is effectively modulating that activity.
Complement biology involves three major activation routes—the classical, lectin, and alternative pathways—that converge on downstream effector mechanisms, including the generation of inflammatory mediators and the formation of the terminal complement complex C5b-9, which can assemble as the membrane attack complex (MAC) on susceptible cell surfaces. Amplification loops, endogenous regulators, cleavage products, and crosstalk among the pathways add further complexity.
For drug developers, this means that a single analytical readout is rarely sufficient to characterize complement activity comprehensively. A more informative strategy combines functional assays, fit-for-purpose biological samples, and multiparametric measurements.
Functional Activity Matters as Much as Protein Quantity
Quantitative assays can establish how much of a complement component is present. Functional assays answer a different question: Does the complement cascade remain capable of activation under the defined experimental conditions?
Hemolytic assays remain an established approach for assessing complement function. In these assays, complement activation ultimately results in membrane damage and erythrocyte lysis, providing an integrated readout of cascade activity. CH50 and AH50 assays are commonly used to evaluate the functional integrity of the classical and alternative pathways, respectively.
For therapeutic development, the same biological principle can be applied to hemolytic inhibition assays. Instead of simply establishing baseline complement activity, researchers can evaluate whether an inhibitor reduces complement-mediated hemolysis and characterize inhibition across a concentration range.
Creative Biolabs provides hemolysis inhibition profiling and complement activity assessment, including approaches based on CH50/AH50 measurements and concentration–response analysis.
The broader lesson is important: target binding should not automatically be equated with functional pathway inhibition. Orthogonal functional testing can help establish whether molecular engagement produces the intended downstream biological effect.
Pre-Analytical Variables Can Change the Answer
Even a well-designed assay can produce misleading conclusions if sample collection and handling are inappropriate.
Complement is particularly sensitive to pre-analytical conditions because activation can continue after blood collection. Ex vivo activation may therefore generate complement fragments that were not present at the same concentrations in vivo, while inappropriate storage or repeated freeze-thaw cycles may compromise sample integrity and alter measured complement activity. This is not merely a theoretical concern.
A systematic review of complement analysis identified 376 publications and selected 92 studies for full-text analysis. Forty-five studies (49%) used the correct sample type and technique, 25 studies (27%) did not, and a further 22 (24%) did not specify the sample type used. The authors warned that inappropriate procedures can lead to misinterpretation of complement biomarker levels and make comparisons between studies more difficult. Sample choice should therefore follow the biological question.
Serum is generally appropriate when the objective is to assess the ability of complement to activate functionally. For measurement of activation products, appropriately anticoagulated plasma—particularly EDTA plasma—is often preferred because complement activation needs to be inhibited during and after collection.
Researchers should consequently define collection tubes, processing times, temperatures, storage conditions, and freeze-thaw limits as part of the experimental design—not as administrative details after an assay has already been selected.
For studies requiring controlled complement matrices, Creative Biolabs provides human and animal sera and plasmas, including materials with preserved complement activity and protein-depleted matrices for research applications. Such materials can be useful when experiments require defined complement activity, appropriate controls, or investigation of individual pathway components.
Multiplex Analysis Adds Biological Context
Functional assays establish whether a pathway is active or inhibited, but they do not necessarily explain the molecular changes underlying that phenotype. This is where multiplex analysis can add another layer of information.
The complement system contains numerous proteins, regulators, cleavage products, and downstream effectors. Changes across several of these analytes may occur simultaneously. Measuring a single component can therefore overlook biologically meaningful patterns or provide an incomplete interpretation of therapeutic response.
Multiplex assays allow multiple complement-related analytes to be evaluated from the same sample. This can be especially valuable when sample volume is limited or when researchers need to compare changes across several biomarkers under identical experimental conditions.
Creative Biolabs’ complement multiplex assay platform supports analysis of serum, plasma, tissue, and culture supernatant samples. Panels can be configured around complement-related targets such as C2, C4b, C5, C5a, C9, mannose-binding lectin, factor D, factor I, and properdin.
Importantly, multiplexing should not simply mean “measuring more.” The selected panel should reflect the mechanism being investigated. For example, combining upstream components, activation products, regulators, and terminal pathway markers may help researchers determine not only whether complement activity changes, but also where that change is occurring within the cascade.
Toward an Orthogonal Complement Testing Strategy
A robust complement research program can therefore be built around three complementary layers of evidence:
1. Functional activity
Use pathway-relevant functional assays to determine whether complement activation occurs and whether a therapeutic candidate meaningfully inhibits it.
2. Fit-for-purpose samples
Choose serum or plasma according to the intended measurement and standardize collection, processing, storage, and freeze-thaw conditions.
3. Molecular characterization
Measure relevant complement components, activation products, and regulatory factors to provide mechanistic context for functional observations.
This integrated approach can help distinguish outcomes that might otherwise appear identical. Two candidates may demonstrate similar target binding, for example, while differing substantially in their ability to suppress downstream complement activity. Likewise, an apparent increase in an activation marker may reflect biology—or pre-analytical activation introduced during sample handling.
As complement-targeted therapeutics continue to advance, assay strategy will remain central to data quality. The most useful experimental question is increasingly not simply “What can we measure?” but rather “Which combination of measurements best demonstrates the biological mechanism?”
Researchers developing complement-targeted therapeutics or investigating complement pathway biology can explore Creative Biolabs’ resources for hemolytic inhibition assays, complement-active sera and plasmas, and multiplex complement analysis to support integrated experimental strategies.
Explore solutions for advancing complement therapeutics research at Creative Biolabs: https://www.creative-biolabs.com/complement-therapeutics/.
Author Bio
Dr. Emily R. Coleman is a senior scientist at Creative Biolabs with a background in immunology, oncology research, and translational biotherapeutic development. Her work focuses on translating complex biological mechanisms into practical experimental strategies for next generation therapeutic discovery, with particular expertise in tumor immunology and antibody engineering.
At Creative Biolabs, she provides scientific insight across multiple R&D domains, including antibody discovery and development, gene and cell therapy research, and translational assay design. She is particularly focused on improving the connection between mechanistic biology and predictive preclinical models to support more effective therapeutic development across immune related disease areas.
About Creative Biolabs
Creative Biolabs provides research services, reagents, assay platforms, and customized solutions supporting complement biology and therapeutic development, including functional testing, complement inhibitor evaluation, specialized sera and plasmas, and multiplex complement analysis.
